Summary
Cimetidine is thought to inhibit suppressor T-lymphocyte function and preliminary evidence from a randomized trial indicated that it might prolong survival for patients with operable and inoperable gastric cancer. The British Stomach Cancer Group conducted a randomized, double-blind, placebo-controlled trial examining the effects of cimetidine (400 mg or 800 mg twice a day) on the survival of patients with early (stages I, II and III: n = 229) and advanced (stages IVa and IVb: n = 201) gastric cancer. The primary end point was death. A total of 442 patients were randomized by 59 consultants in 39 hospitals between February 1990 and March 1995. Log-rank survival analysis was used to assess differences between the groups. Three hundred and forty patients died during the study: 166 (49%) in the cimetidine treatment groups and 174 (51%) in the placebo groups. Median survival for patients receiving cimetidine was 13 months (95% confidence interval (CI) 9–16 months) and 11 months in the placebo arm (95% CI 9–14 months). There was no significant difference in survival between the two treatment groups (P = 0.42) or between different doses of cimetidine tablets (P = 0.46). Five-year survival of those patients randomized to cimetidine was 21% compared to 18% for those patients randomized to placebo. Cimetidine at a dose of 400 mg or 800 mg twice a day does not have a significant influence on the survival of patients with gastric cancer compared to placebo.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adams, WJ & Morris, DL (1997). Pilot study–cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 80: 15–21.
Allum, WH, Powell, DJ, McConkey, CC & Fielding, JW (1989a). Gastric cancer: a 25-year review. Br J Surg 76: 535–540.
Allum, WH, Hallissey, MT & Kelly, KA (1989b). Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1: 571–574.
Burtin, C, Noirot, C, Scheinmann Galoppin, L, Sabolovic, D & Bernard, P (1988). Clinical improvement in advanced cancer disease after treatment combining histamine and H2 antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol 24: 161–167.
Cuschieri, A, Fayers, P & Fielding, J et al (1996). Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347: 995–999.
Franceschi, S, Levi, F & La Vecchia, C (1994). Epidemiology of gastric cancer in Europe. Eur J Cancer Prev 3: 5–10.
Fuchs, CS & Mayer, RJ (1995). Gastric carcinoma. N Engl J Med 333: 32–41.
Gold, GE, Malamud, SC, LaRosa, F, Seder, R & Osband, ME (1993). Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide. J Immunother 13: 213–221.
Griswold, DE, Alessi, S, Badger, AM, Poste, G & Hanna, N (1984). Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol 132: 3054–3057.
Hallissey, MT, Dunn, JA, Ward, LC & Allum, WH (1994). The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343: 1309–1312.
Hermans, J, Bonenkamp, JJ, Boon, MC, Bunt, AMG, Ohyama, S, Sasako, M & Van de Velde, CHJ (1993). Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomised trials. J Clin Oncol 11: 1441–1447.
Kaplan, EL & Meier, P (1958). Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457
Kelsen, DP (1996). Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 23: 379–389.
Kikuchi, Y, Oomori, K, Kizawa, I & Kato, K (1986). Augmented natural killer activity in ovarian cancer patients treated with cimetidine. Eur J Cancer Clin Oncol 22: 1037–1043.
Links, M, Clingan, PR, Phadke, K, O'Baugh, J, Legge, J, Adams, WJ, Ross, WB & Morris, DL (1995). A randomised trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol 21: 523–525.
Peto, R, Pike, MC, Armitage, P, Breslow, NE, Cox, DR, Howard, SV, Mantel, N, McPherson, K, Peto, J & Smith, PG (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and example. Br J Cancer 35: 1–39.
Primrose, JN, Miller, GV, Preston, SR, Gokhale, J, Ambrose, NS, Ward, UM, Mills, JG, Ehsanullah, RSB & Darekar, B the Yorkshire GI Tumour Group (1998). A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Gut 42: 17–19.
Rios-Castellanos, E, Sitas, F, Shepherd, NA & Jewell, DP (1992). Changing pattern of gastric cancer in Oxfordshire. Gut 33: 1312–1317.
Sagaster, P, Micksche, M, Flamm, J & Ludwig, H (1995). Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 6: 999–1003.
Svendsen, LB, Ross, C, Knigge, U, Frederiksen, HJ, Graversen, P, Kjaergard, J, Luke, M, Stimpel, H & Sparso, BH (1995). Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 38: 514–518.
Taylor, TV, Boom, SJ, Blower, AL, McMahon, RF & Lawler, W (1988). Healing of a malignant gastric ulcer with cimetidine. J R Coll Surg Edin 33: 339–340.
Tonnesen, H, Knigge, U & Bulow, S et al (1988). Effect of cimetidine on survival after gastric cancer. Lancet 2: 990–992.
Watson, SA, Wilkinson, LJ, Robertson, JR & Hardcastle, JD (1993). Effect of histamine on the growth of human gastro-intestinal tumours: reversal by cimetidine. Gut 34: 1091–1096.
Wils, J (1996). The treatment of advanced gastric cancer. Semin Oncol 23: 397–406.
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Langman, M., Dunn, J., Whiting, J. et al. Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. Br J Cancer 81, 1356–1362 (1999). https://doi.org/10.1038/sj.bjc.6690457
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690457
Keywords
This article is cited by
-
Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis
International Journal of Clinical Oncology (2021)
-
A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients
Journal of Nanobiotechnology (2019)
-
Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer
Gastric Cancer (2011)
-
Cimetidine in colorectal cancer – are the effects immunological or adhesion-mediated?
British Journal of Cancer (2002)